By
May 20, 2021 09:38 PM EDT
(Photo : Getty Images/Greg Nash-Pool) WASHINGTON, DC - MAY 11: Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, speaks during a Senate Health, Education, Labor and Pensions Committee hearing to discuss the ongoing federal response to COVID-19 on May 11, 2021 in Washington, DC.
According to the pharmaceutical companies CEOs, after being administered a Pfizer or Moderna COVID-19 vaccine this year, one might need a booster before the end of the year. Pfizer CEO Albert Bourla said that according to the data, they support the notion that possibly there will be a need for a booster.
UK launches 3rd booster dose trial of 7 Covid vax
By IANS |
0 Views
China to produce over 3 billion Covid vax this year. Image Source: IANS News
London, May 21 : In a first, the UK has launched a new clinical trial that will assess the efficacy of a third booster dose of seven different Covid-19 vaccines on patients immune responses, the media reported.
The trial will assess Covid-19 vaccines of Oxford-AstraZeneca, Pfizer-BioNTech, Moderna, Novavax, Valneva, Janssen and Curevac.
The trial, named Cov-Boost, aims to begin in June and recruit 3,000 people of all ages who had their first dose in December or January, to test if this is worthwhile, the BBC reported on Thursday.
Form 6-K Valneva SE For: May 20 streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Published: May 20, 2021
in the first quarter of 2021 for:
VLA15, currently the only clinical stage vaccine candidate against Lyme disease
Initiation of additional Phase 2 trial to accelerate pediatric development
VLA2001, currently the only inactivated, adjuvanted vaccine candidate for COVID-19 in clinical trials in Europe:
Initiation of pivotal Phase 3 clinical trial
Participation in the world’s first COVID-19 vaccine booster trial in the UK
Publication of Phase 1/2 results
VLA1553, currently the only Phase 3 chikungunya vaccine program worldwide
Recruitment completion for pivotal Phase 3 trial
Successful Nasdaq listing (Q2 event); $107.6 million of gross proceeds
Cash and cash equivalents of €235.9
million at
31, 2021
Q1 2021 cash and cash equivalents do not include proceeds of $107.6 million from the Company’s recent Global Offering